Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban 2.5 mg Bioequivalence Study in Healthy Adults
NCT07807488Phase 1Completed
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Mar 2022
- Primary completion
- Apr 2022
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rivaroxaban in thromboembolism (2 arms), sponsored by The Affiliated Hospital of Qingdao University. Primary endpoints: Maximum Plasma Concentration, Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration and 1 more. Started Mar 2022; status: completed.
02
Drugs
rivaroxaban
03
Conditions
thromboembolism
Beyond the preview
Go deeper on NCT07807488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07807488.